Trials / Completed
CompletedNCT02322528
Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax
Evaluation of Ocular Surface Inflammatory Mediators and Ocular Surface Metrology Effected by Lotemax
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- All
- Age
- 50 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effects of an anti-inflammatory drug (Lotemax®) on the surface of the eye and tear film (a film that coats the eye which is made up of oil and water).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Administration of Lotemax | An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes. |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2014-12-23
- Last updated
- 2015-10-16
- Results posted
- 2015-10-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02322528. Inclusion in this directory is not an endorsement.